

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

### **VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE**

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 21 June 2018, Nanjing Legend Biotech Co., Ltd. (“**Nanjing Legend**”), an indirect subsidiary of the Company has entered into a clinical cooperation agreement with The Second Affiliated Hospital of Xi’an Jiaotong University\* (西安交通大學第二附屬醫院) (“**The Second Affiliated Hospital**”), whereby Nanjing Legend will provide its CAR-T cell therapy product LCAR-L10D (“**LCAR-L10D**”) to conduct clinical study on diffuse large B-cell lymphoma (“**DLBCL**”) (the “**Clinical Study**”). LCAR-L10D is a CAR-T product with multi-target recognition function developed by the exclusive intellectual property team of Nanjing Legend.

As of the date of this announcement, approval for the Clinical Study has been obtained from the Ethics Committee of The Second Affiliated Hospital and the Clinical Study is expected to commence in the near future.

#### **INFORMATION ON DLBCL**

DLBCL is the most common type of malignant B-cell lymphoma and is clinically regarded as highly invasive. Currently, DLBCL can be mainly treated by a combination of chemotherapy with CD20 monoclonal antibody therapy, radiotherapy and hematopoietic stem cell transplantation. Yet, for one third of patients after the first treatment, DLBCL still relapsed and the patients became resistant against the treatment. As the Group believes that CAR-T cell technology possesses significant potential in the clinical treatment of DLBCL cancer, the Group will invest in R&D in this area to capture the emerging opportunities in the relevant clinical treatment market.

## **INFORMATION ON THE SECOND AFFILIATED HOSPITAL**

The Second Affiliated Hospital is a National Grade III A hospital operating directly under the National Health Council and Ministry of Education. It is a modernised hospital with comprehensive facilities that provides medical, education, scientific research and preventive health care services. Based on the previously established clinical research cooperation relationship between Nanjing Legend and The Second Affiliated Hospital, the Clinical Study will commence at The Second Affiliated Hospital with potential expansion to other clinical institutions.

## **INFORMATION ON THE GROUP AND NANJING LEGEND**

The Group is principally engaged in the provision of (i) bio-science services and products, (ii) industrial synthetic biology products, and (iii) precision immune-cell therapy.

Nanjing Legend is a limited liability company incorporated in the People's Republic of China and is an indirect subsidiary of the Company.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate to deal in the securities of the Company.**

By order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 22 June 2018

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.*

\* *For identification purposes only*